[
  {
    "topic": "pharmacology",
    "question": "Which of the following is LEAST likely to be used in metastatic breast cancer?",
    "options": [
      "Trastuzumab in HER2-positive tumors",
      "Tamoxifen in ER-negative tumors",
      "Paclitaxel monotherapy",
      "CMF"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a determinant of chemotherapy choice in breast cancer?",
    "options": [
      "Axillary node involvement",
      "Patient\u2019s shoe size",
      "Tumor HER2 status",
      "Financial status"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which prognostic factor does NOT influence chemotherapy choice?",
    "options": [
      "Menopausal status",
      "HER2 status",
      "Ki-67 index",
      "Patient\u2019s favorite color"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which drug is an example of a microtubule super-stabilizer?",
    "options": [
      "Cyclophosphamide",
      "Paclitaxel",
      "5-Fluorouracil",
      "Doxorubicin"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "The AC-T regimen consists of:",
    "options": [
      "Adriamycin + Capecitabine, then Taxotere",
      "Anthracycline + Cisplatin, then Taxane",
      "Adriamycin + Cyclophosphamide, then Taxol",
      "Aromatase inhibitor + Cyclophosphamide, then Trastuzumab"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a component of the CMF regimen?",
    "options": [
      "Cyclophosphamide",
      "Methotrexate",
      "Mitomycin-C",
      "Fluorouracil"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is TRUE about triple-negative breast cancer?",
    "options": [
      "It is best treated with trastuzumab",
      "It lacks ER, PR, and HER2 expression",
      "It is HER2-positive",
      "It responds well to hormonal therapy"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a common adjuvant regimen for early breast cancer in Nigeria?",
    "options": [
      "CMF",
      "Vinorelbine + Cisplatin",
      "AC-T",
      "Capecitabine monotherapy"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "In ER-positive, HER2-negative breast cancer, which agent is typically added to chemotherapy?",
    "options": [
      "Cisplatin",
      "Gemcitabine",
      "Trastuzumab",
      "Tamoxifen"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a platinum-based chemotherapeutic agent?",
    "options": [
      "Vinorelbine",
      "Doxorubicin",
      "Carboplatin",
      "Docetaxel"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a 1st-generation chemotherapy regimen for breast cancer?",
    "options": [
      "TC",
      "TAC",
      "CMF",
      "AC-T"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is LEAST likely to be used in triple-negative breast cancer?",
    "options": [
      "AC-T",
      "TC",
      "Carboplatin",
      "Tamoxifen"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a goal of chemotherapy in breast cancer management?",
    "options": [
      "Managing metastatic disease",
      "Complete tumor resection",
      "Slowing malignant cell growth",
      "Preventing recurrence"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a long-term side effect of breast cancer chemotherapy?",
    "options": [
      "Cardiomyopathy",
      "Hair loss",
      "Nausea",
      "Fatigue"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "All of the following are anthracyclines EXCEPT:",
    "options": [
      "Paclitaxel",
      "Mitoxantrone",
      "Doxorubicin",
      "Epirubicin"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a recommended pre-treatment work-up for chemotherapy?",
    "options": [
      "Complete blood count (FBC)",
      "Echocardiography",
      "Bone density scan",
      "MRI of the brain"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a short-term side effect of chemotherapy?",
    "options": [
      "Mucositis",
      "Leukemia",
      "Neuropathy",
      "Alopecia"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Adjuvant chemotherapy is most critical in which of the following cases?",
    "options": [
      "Stage 0 DCIS",
      "Lymph node-positive disease",
      "HER2-negative, ER-positive tumors",
      "Post-menopausal patients with small tumors"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "In taxane-resistant TNBC, which drug is under clinical trial?",
    "options": [
      "Gemcitabine",
      "Ixabepilone",
      "Capecitabine",
      "Eribulin"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a hormonal therapy agent?",
    "options": [
      "Aromatase inhibitor",
      "Trastuzumab",
      "Tamoxifen",
      "Fulvestrant"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which drug is an antibody-drug conjugate used in HER2-positive breast cancer?",
    "options": [
      "Trastuzumab emtansine (T-DM1)",
      "Tamoxifen",
      "Vinorelbine",
      "Mitomycin-C"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a side effect of anthracyclines?",
    "options": [
      "Cardiomyopathy",
      "Peripheral neuropathy",
      "Alopecia",
      "Bone demineralization"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "For locally advanced breast cancer (LABC), the standard of care is:",
    "options": [
      "Hormonal therapy",
      "Immediate surgery",
      "Neo-adjuvant chemotherapy",
      "Radiation alone"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which regimen combines an anthracycline and a taxane?",
    "options": [
      "Capecitabine monotherapy",
      "CMF",
      "TC",
      "AC-T"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a recommended strategy for managing chemotherapy-induced nausea?",
    "options": [
      "Opioids",
      "Dexamethasone",
      "5-HT3 antagonists",
      "NK1 receptor antagonists"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which chemotherapeutic agent is classified as an antimetabolite?",
    "options": [
      "5-Fluorouracil",
      "Cyclophosphamide",
      "Vinorelbine",
      "Docetaxel"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which chemotherapy backbone is used in the 3rd generation of breast cancer regimens?",
    "options": [
      "Anthracycline",
      "Taxane",
      "Antimetabolite",
      "Platinum"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "In HER2-positive breast cancer, which agent is typically added to chemotherapy?",
    "options": [
      "Trastuzumab",
      "Tamoxifen",
      "Mitomycin-C",
      "Capecitabine"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "A patient with taxane-resistant TNBC is LEAST likely to benefit from:",
    "options": [
      "Eribulin",
      "Carboplatin",
      "Ixabepilone",
      "Paclitaxel"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Neo-adjuvant chemotherapy is primarily indicated in which scenario?",
    "options": [
      "Inflammatory breast cancer",
      "Post-surgical recurrence",
      "DCIS (Stage 0)",
      "Stage IV metastatic disease"
    ],
    "correct_option": 0
  }
]